The latest edition of an annual report finds new cases continue to rise and outcomes have worsened for some cancers.

Though the findings are positive overall, survival increases since the mid-1990s are especially notable for more fatal cancers. For example, survival rates for myeloma, a bone marrow cancer, jumped from 32% to 62%, liver cancer from 7% to 22% and lung cancer from 15% to 28%.

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary tumors.

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease.

Researchers found better detection, treatment and decreased smoking have been immensely helpful in reducing deaths due to cancer.

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had significantly lower rates of overall survival versus ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse events.

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

According to the data on some 990,000 people diagnosed with cancer in 2016 across the country, prostate cancer logged the highest net survival rate.

Prostate cancer is the most common cancer in men, with about 1-in-8 expected to be diagnosed in their lifetime.